OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07 Submission of Matters to a Vote of Security
Holders.

Ocular Therapeutix held its Annual Meeting of Stockholders on
June1, 2017. The following is a summary of the matters voted on
at that meeting.

(a)

Ocular Therapeutixs stockholders elected Amarpreet Sawhney,
Ph.D., Bruce Peacock and Jeffrey S. Heier, M.D. as ClassIII
directors to serve until the 2020 Annual Meeting of
Stockholders, each such director to hold office until his
successor has been duly elected and qualified. The results
of the stockholders vote with respect to the election of
such ClassIII directors were as follows:

Name

VotesFor

Votes Withheld

Broker Non-Votes

Amarpreet Sawhney, Ph.D.

12,899,564

2,127,299

9,511,468

Bruce Peacock

12,906,842

2,120,021

9,511,468

Jeffrey S. Heier, M.D.

12,661,305

2,365,558

9,511,468

(b)

Ocular Therapeutixs stockholders ratified the selection of
PricewaterhouseCoopers LLP as Ocular Therapeutixs
independent registered public accounting firm for the
current fiscal year. The result of the stockholders vote
with respect to such ratification were as follows:

For

Against

Abstain

BrokerNon-Votes

24,457,147

75,696

5,488


About OCULAR THERAPEUTIX, INC. (NASDAQ:OCUL)

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. It also has an intravitreal hydrogel depot, which is in preclinical development for the treatment of diseases and conditions of the back of the eye, including wet age-related macular degeneration (wet AMD).

OCULAR THERAPEUTIX, INC. (NASDAQ:OCUL) Recent Trading Information

OCULAR THERAPEUTIX, INC. (NASDAQ:OCUL) closed its last trading session up +0.51 at 10.71 with 809,053 shares trading hands.